Barclays’s Galmed Pharmaceuticals GLMD Stock Holding History

Barclays’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-2	Closed	-$2K	–	7123
2018 Q4	$2K	Buy	+2	New	+$3.49K	﹤0.01%	6712
2018 Q3	–	Sell	-8	Closed	-$18K	–	7218
2018 Q2	$18K	Buy	+8	New	+$11.6K	﹤0.01%	6235
2016 Q2	–	Sell	-13	Closed	-$10K	–	6422
2016 Q1	$10K	Buy	+13	New	+$12.7K	﹤0.01%	5466

Other funds holding GLMD

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

KCM

Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return

FMBTD

First Midwest Bank Trust Division Joliet, Illinois $777M AUM 29.48% 1-Year Est. Return

PAWC

P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return

Barclays's GLMD Position: Q1 2019 in Review

Barclays sold out of Galmed Pharmaceuticals (GLMD) in Q1 2019, closing a stake of 2 shares — an estimated $2K sold.

Barclays first reported a position in GLMD in Q1 2016 and held it in 3 quarters. The position peaked at $18K in Q2 2018. 34 funds tracked by Wall St. Rank hold GLMD as of Q1 2019.

Barclays reported no remaining Galmed Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
Barclays sold 2 Galmed Pharmaceuticals shares in Q1 2019, an estimated $2K.
Barclays first reported a position in Galmed Pharmaceuticals in Q1 2016 and held it in 3 quarters.
Barclays's Galmed Pharmaceuticals position peaked at $18K in Q2 2018.
34 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q1 2019.

Based on Barclays's 13F filing for Q1 2019, filed 15 May 2019.